{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 2256, "pageSize": 60, "pageCount": 5333, "rows": [ { "docId": "019dd923-622c-750b-8b9b-b1168ab6bd8a", "docSlug": "ddfbb08119f4", "documentTitle": "Multiple holdings (Pershing Square portfolio)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2016-04-26 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/2k4mXnsQRXfQoMrYZ3NO0BmZXeZf_fJtQS7qPHQjCL0/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9kZGZiYjA4MTE5ZjQvcDAwMS5qcGc", "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-b1168ab6bd8a/1", "deckHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a#slide-1", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 1, "beatId": "159a4f39-f2d2-4513-bf1f-2bae8fb224d3", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Situation & Context", "beatSlug": "consultants-gambit-situation-context", "evidence": "The presentation starts with a review of the 2016 YTD fund performance and a disclaimer.", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": "https://imgproxy.kitesheet.com/eAF7VNoCzZIoU9Ysz84LFAVmUivAic64dhzqcp4NGyw/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9kZGZiYjA4MTE5ZjQvcDAwMS5wbmc", "thumbSrc": "https://imgproxy.kitesheet.com/r0yrioay2P0Z7l8Hgqb0Mx-q53vtWmnI1XtaeIKJdA0/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9kZGZiYjA4MTE5ZjQvcDAwMS5qcGc", "thumbSrcAlt": "https://imgproxy.kitesheet.com/2gmDZ0-C2t8tuoUtDFVd0RVdIs9tH-ji8LoPKxatYSw/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9kZGZiYjA4MTE5ZjQvcDAwMS5wbmc" }, { "docId": "019dd923-622c-750b-8b9b-b1168ab6bd8a", "docSlug": "ddfbb08119f4", "documentTitle": "Multiple holdings (Pershing Square portfolio)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2016-04-26 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 2, "slideType": "disclaimer", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-b1168ab6bd8a/2", "deckHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a#slide-2", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 1, "beatId": "159a4f39-f2d2-4513-bf1f-2bae8fb224d3", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Situation & Context", "beatSlug": "consultants-gambit-situation-context", "evidence": "The presentation starts with a review of the 2016 YTD fund performance and a disclaimer.", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-b1168ab6bd8a", "docSlug": "ddfbb08119f4", "documentTitle": "Multiple holdings (Pershing Square portfolio)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2016-04-26 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 3, "slideType": "agenda", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-b1168ab6bd8a/3", "deckHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a#slide-3", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 1, "beatId": "159a4f39-f2d2-4513-bf1f-2bae8fb224d3", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Situation & Context", "beatSlug": "consultants-gambit-situation-context", "evidence": "The presentation starts with a review of the 2016 YTD fund performance and a disclaimer.", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-b1168ab6bd8a", "docSlug": "ddfbb08119f4", "documentTitle": "Multiple holdings (Pershing Square portfolio)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2016-04-26 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 4, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-b1168ab6bd8a/4", "deckHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a#slide-4", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 1, "beatId": "159a4f39-f2d2-4513-bf1f-2bae8fb224d3", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Situation & Context", "beatSlug": "consultants-gambit-situation-context", "evidence": "The presentation starts with a review of the 2016 YTD fund performance and a disclaimer.", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-b1168ab6bd8a", "docSlug": "ddfbb08119f4", "documentTitle": "Multiple holdings (Pershing Square portfolio)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2016-04-26 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 5, "slideType": "kpi_overview", "function": "compare_peers", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-b1168ab6bd8a/5", "deckHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a#slide-5", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 1, "beatId": "159a4f39-f2d2-4513-bf1f-2bae8fb224d3", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Situation & Context", "beatSlug": "consultants-gambit-situation-context", "evidence": "The presentation starts with a review of the 2016 YTD fund performance and a disclaimer.", "position": 0, "confidence": 0.8, "parentBeatName": "Setup", "parentBeatSlug": "setup" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-b1168ab6bd8a", "docSlug": "ddfbb08119f4", "documentTitle": "Multiple holdings (Pershing Square portfolio)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2016-04-26 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 6, "slideType": "peer_benchmark", "function": "compare_peers", "notes": "The chart highlights the significant outperformance of Pershing Square relative to the S&P 500 index over the specified period.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-b1168ab6bd8a/6", "deckHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a#slide-6", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-b1168ab6bd8a", "docSlug": "ddfbb08119f4", "documentTitle": "Multiple holdings (Pershing Square portfolio)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2016-04-26 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 7, "slideType": "comparison_table", "function": "analyze_data", "notes": "The slide uses a split-table format to contrast positive and negative performance contributors.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-b1168ab6bd8a/7", "deckHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a#slide-7", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-b1168ab6bd8a", "docSlug": "ddfbb08119f4", "documentTitle": "Multiple holdings (Pershing Square portfolio)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2016-04-26 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 8, "slideType": "kpi_overview", "function": "analyze_data", "notes": "The slide uses a table to demonstrate historical performance attribution.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-b1168ab6bd8a/8", "deckHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a#slide-8", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-b1168ab6bd8a", "docSlug": "ddfbb08119f4", "documentTitle": "Multiple holdings (Pershing Square portfolio)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2016-04-26 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 9, "slideType": "appendix_data", "function": "analyze_data", "notes": "The slide includes a footnote clarifying the relationship between core funds and co-investment vehicles.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-b1168ab6bd8a/9", "deckHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a#slide-9", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-b1168ab6bd8a", "docSlug": "ddfbb08119f4", "documentTitle": "Multiple holdings (Pershing Square portfolio)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2016-04-26 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 10, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-b1168ab6bd8a/10", "deckHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a#slide-10", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-b1168ab6bd8a", "docSlug": "ddfbb08119f4", "documentTitle": "Multiple holdings (Pershing Square portfolio)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2016-04-26 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 11, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-b1168ab6bd8a/11", "deckHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a#slide-11", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-b1168ab6bd8a", "docSlug": "ddfbb08119f4", "documentTitle": "Multiple holdings (Pershing Square portfolio)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2016-04-26 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 12, "slideType": "executive_summary", "function": "establish_context", "notes": "This slide serves as a company profile for an activist investor presentation.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-b1168ab6bd8a/12", "deckHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a#slide-12", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-b1168ab6bd8a", "docSlug": "ddfbb08119f4", "documentTitle": "Multiple holdings (Pershing Square portfolio)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2016-04-26 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 13, "slideType": "key_messages", "function": "establish_context", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-b1168ab6bd8a/13", "deckHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a#slide-13", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-b1168ab6bd8a", "docSlug": "ddfbb08119f4", "documentTitle": "Multiple holdings (Pershing Square portfolio)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2016-04-26 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 14, "slideType": "key_messages", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-b1168ab6bd8a/14", "deckHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a#slide-14", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-b1168ab6bd8a", "docSlug": "ddfbb08119f4", "documentTitle": "Multiple holdings (Pershing Square portfolio)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2016-04-26 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 15, "slideType": "peer_benchmark", "function": "compare_peers", "notes": "The chart highlights Mondelez's underperformance relative to peers, with Mondelez shown in red.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-b1168ab6bd8a/15", "deckHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-b1168ab6bd8a#slide-15", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9e6bdedc5eed", "docSlug": "f39479b88775", "documentTitle": "Herbalife, Ltd. (HLF)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 61, "slideType": "appendix_disclosure", "function": "cite_precedent", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9e6bdedc5eed/61", "deckHref": "/decks/019dd923-622c-750b-8b9b-9e6bdedc5eed", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9e6bdedc5eed#slide-61", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9e6bdedc5eed", "docSlug": "f39479b88775", "documentTitle": "Herbalife, Ltd. (HLF)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 62, "slideType": "cite_precedent", "function": "cite_precedent", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9e6bdedc5eed/62", "deckHref": "/decks/019dd923-622c-750b-8b9b-9e6bdedc5eed", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9e6bdedc5eed#slide-62", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9e6bdedc5eed", "docSlug": "f39479b88775", "documentTitle": "Herbalife, Ltd. (HLF)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 63, "slideType": "cite_precedent", "function": "cite_precedent", "notes": "The slide highlights the specific criteria (30 participants, 3 levels) for criminal liability in China.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9e6bdedc5eed/63", "deckHref": "/decks/019dd923-622c-750b-8b9b-9e6bdedc5eed", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9e6bdedc5eed#slide-63", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-add9defaff10", "docSlug": "957eafbe1ec6", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square Holdings", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2016-04-25 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 1, "slideType": "executive_summary", "function": "summarize", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/sLiHlM9t5oH8_fOplby3VSKT9mgEpgXoERtfTkr-zNE/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85NTdlYWZiZTFlYzYvcDAwMS5wbmc", "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-add9defaff10/1", "deckHref": "/decks/019dd923-622c-750b-8b9b-add9defaff10", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-add9defaff10#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/qqe2bH9VxdIoS0Qt9sDRjPNwRmsEo1AIvAv213SG4i4/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85NTdlYWZiZTFlYzYvcDAwMS5qcGc", "thumbSrc": "https://imgproxy.kitesheet.com/GX159N4WoqkoikOkMjukKRG2iZ8Pu7g1K8fMrIBAQio/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85NTdlYWZiZTFlYzYvcDAwMS5wbmc", "thumbSrcAlt": "https://imgproxy.kitesheet.com/SqR7pSDo3gvCcb_ldWon5Z-nmjVQ3G_SpDfEOHuUmaE/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85NTdlYWZiZTFlYzYvcDAwMS5qcGc" }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": "Pershing Square Capital Management, L.P. logo and name present.", "imagePath": "https://imgproxy.kitesheet.com/0X1_jYXqkcPb9XEEB3HFF__hT3X4f6IZVcYapQDrz4E/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy80OTM0ZDY4N2NiMzgvcDAwMS5qcGc", "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/1", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-1", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 1, "beatId": "ba62bddc-1640-4f2a-9149-d04308775419", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Setup", "beatSlug": "setup", "evidence": "Introduction to Valeant Pharmaceuticals", "position": 0, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": "https://imgproxy.kitesheet.com/pVfpDMMQpAGWnPPR3psykrJDu9RQpTMVRe-mA6UPbsQ/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy80OTM0ZDY4N2NiMzgvcDAwMS5wbmc", "thumbSrc": "https://imgproxy.kitesheet.com/pRP8YvYPEpJw9gB1FzHALccBCdQK1z8E1njV1lIuE7k/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy80OTM0ZDY4N2NiMzgvcDAwMS5qcGc", "thumbSrcAlt": "https://imgproxy.kitesheet.com/XldDQbFnm2mdsk5CLhK2ipubfaYSlffxBH-x1jHavT8/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy80OTM0ZDY4N2NiMzgvcDAwMS5wbmc" }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 2, "slideType": "disclaimer", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/2", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-2", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 1, "beatId": "ba62bddc-1640-4f2a-9149-d04308775419", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Setup", "beatSlug": "setup", "evidence": "Introduction to Valeant Pharmaceuticals", "position": 0, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 3, "slideType": "disclaimer", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/3", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-3", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 1, "beatId": "ba62bddc-1640-4f2a-9149-d04308775419", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Setup", "beatSlug": "setup", "evidence": "Introduction to Valeant Pharmaceuticals", "position": 0, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 4, "slideType": "executive_summary", "function": "establish_context", "notes": "This slide serves as a company profile/introductory slide for an activist investor deck.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/4", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-4", "loopMatches": [], "arcBeatMatches": [ { "to": 4, "from": 1, "beatId": "ba62bddc-1640-4f2a-9149-d04308775419", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Setup", "beatSlug": "setup", "evidence": "Introduction to Valeant Pharmaceuticals", "position": 0, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 5, "slideType": "executive_summary", "function": "establish_context", "notes": "The slide outlines the core pillars of the Valeant business model, including M&A, leverage, and decentralized structure.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/5", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-5", "loopMatches": [], "arcBeatMatches": [ { "to": 9, "from": 5, "beatId": "0d8ab027-41f9-4204-ab2e-76e52fbb62fb", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Complication", "beatSlug": "complication", "evidence": "Discussion of recent events and challenges", "position": 1, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 6, "slideType": "key_messages", "function": "establish_context", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/6", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-6", "loopMatches": [], "arcBeatMatches": [ { "to": 9, "from": 5, "beatId": "0d8ab027-41f9-4204-ab2e-76e52fbb62fb", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Complication", "beatSlug": "complication", "evidence": "Discussion of recent events and challenges", "position": 1, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 7, "slideType": "before_after", "function": "illustrate_case", "notes": "The chart uses callout boxes to link specific dates and events to the share price trajectory.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/7", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-7", "loopMatches": [], "arcBeatMatches": [ { "to": 9, "from": 5, "beatId": "0d8ab027-41f9-4204-ab2e-76e52fbb62fb", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Complication", "beatSlug": "complication", "evidence": "Discussion of recent events and challenges", "position": 1, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 8, "slideType": "timeline", "function": "frame_situation", "notes": "The slide uses a line chart with callout boxes to correlate specific news events with stock price volatility.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/8", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-8", "loopMatches": [], "arcBeatMatches": [ { "to": 9, "from": 5, "beatId": "0d8ab027-41f9-4204-ab2e-76e52fbb62fb", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Complication", "beatSlug": "complication", "evidence": "Discussion of recent events and challenges", "position": 1, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 9, "slideType": "preempt_rebuttal", "function": "preempt_rebuttal", "notes": "Uses a timeline-annotated line chart to frame market volatility as a series of events to be addressed.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/9", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-9", "loopMatches": [], "arcBeatMatches": [ { "to": 9, "from": 5, "beatId": "0d8ab027-41f9-4204-ab2e-76e52fbb62fb", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Complication", "beatSlug": "complication", "evidence": "Discussion of recent events and challenges", "position": 1, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 10, "slideType": "key_messages", "function": "establish_context", "notes": "The slide uses a simple list format to explain the value proposition of specialty pharmacies followed by a logo grid of industry participants.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/10", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-10", "loopMatches": [], "arcBeatMatches": [ { "to": 16, "from": 10, "beatId": "8c9c2453-1cf4-4b69-b170-2662e00c1f90", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Evidence", "beatSlug": "evidence", "evidence": "Presentation of facts and data to support Valeant's position", "position": 2, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 11, "slideType": "key_messages", "function": "frame_situation", "notes": "This slide is part of a series exposing the Valeant-Philidor relationship.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/11", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-11", "loopMatches": [], "arcBeatMatches": [ { "to": 16, "from": 10, "beatId": "8c9c2453-1cf4-4b69-b170-2662e00c1f90", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Evidence", "beatSlug": "evidence", "evidence": "Presentation of facts and data to support Valeant's position", "position": 2, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 12, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide uses a value-chain diagram to illustrate the structural change in the supply chain.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/12", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-12", "loopMatches": [], "arcBeatMatches": [ { "to": 16, "from": 10, "beatId": "8c9c2453-1cf4-4b69-b170-2662e00c1f90", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Evidence", "beatSlug": "evidence", "evidence": "Presentation of facts and data to support Valeant's position", "position": 2, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 13, "slideType": "expose_contradiction", "function": "expose_contradiction", "notes": "The slide highlights the contradiction between Valeant's accounting consolidation of Philidor and their public claim of non-control.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/13", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-13", "loopMatches": [], "arcBeatMatches": [ { "to": 16, "from": 10, "beatId": "8c9c2453-1cf4-4b69-b170-2662e00c1f90", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Evidence", "beatSlug": "evidence", "evidence": "Presentation of facts and data to support Valeant's position", "position": 2, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 14, "slideType": "timeline", "function": "expose_contradiction", "notes": "The slide uses color-coding to distinguish between Valeant-related events and Philidor-related events, illustrating the opaque nature of their business relationship.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/14", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-14", "loopMatches": [], "arcBeatMatches": [ { "to": 16, "from": 10, "beatId": "8c9c2453-1cf4-4b69-b170-2662e00c1f90", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Evidence", "beatSlug": "evidence", "evidence": "Presentation of facts and data to support Valeant's position", "position": 2, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 15, "slideType": "timeline", "function": "expose_contradiction", "notes": "The timeline uses color-coding to distinguish between entities involved in the dispute.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/15", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-15", "loopMatches": [], "arcBeatMatches": [ { "to": 16, "from": 10, "beatId": "8c9c2453-1cf4-4b69-b170-2662e00c1f90", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Evidence", "beatSlug": "evidence", "evidence": "Presentation of facts and data to support Valeant's position", "position": 2, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 16, "slideType": "expose_contradiction", "function": "expose_contradiction", "notes": "The slide uses a direct quote from a legal complaint to undermine the credibility of the subject.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/16", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-16", "loopMatches": [], "arcBeatMatches": [ { "to": 16, "from": 10, "beatId": "8c9c2453-1cf4-4b69-b170-2662e00c1f90", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Evidence", "beatSlug": "evidence", "evidence": "Presentation of facts and data to support Valeant's position", "position": 2, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 17, "slideType": null, "function": null, "notes": "Image file at /tmp/legacy-images/4934d687cb38/slides/017.jpg does not exist on disk; unable to inspect contents.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/17", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-17", "loopMatches": [], "arcBeatMatches": [ { "to": 21, "from": 17, "beatId": "f826f826-9857-48f7-81f2-57a1bd4e0426", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Preempt Rebuttal", "beatSlug": null, "evidence": "Addressing potential criticisms and rebuttals", "position": 3, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 18, "slideType": "timeline", "function": "expose_contradiction", "notes": "The slide uses color-coded boxes to distinguish between entities involved in the timeline events.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/18", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-18", "loopMatches": [], "arcBeatMatches": [ { "to": 21, "from": 17, "beatId": "f826f826-9857-48f7-81f2-57a1bd4e0426", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Preempt Rebuttal", "beatSlug": null, "evidence": "Addressing potential criticisms and rebuttals", "position": 3, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 19, "slideType": "key_messages", "function": "establish_context", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/19", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-19", "loopMatches": [], "arcBeatMatches": [ { "to": 21, "from": 17, "beatId": "f826f826-9857-48f7-81f2-57a1bd4e0426", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Preempt Rebuttal", "beatSlug": null, "evidence": "Addressing potential criticisms and rebuttals", "position": 3, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 20, "slideType": "precedent_table", "function": "cite_precedent", "notes": "The table serves as a precedent for regulatory risk and financial impact in the pharmaceutical industry.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/20", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-20", "loopMatches": [], "arcBeatMatches": [ { "to": 21, "from": 17, "beatId": "f826f826-9857-48f7-81f2-57a1bd4e0426", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Preempt Rebuttal", "beatSlug": null, "evidence": "Addressing potential criticisms and rebuttals", "position": 3, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 21, "slideType": "preempt_rebuttal", "function": "preempt_rebuttal", "notes": "The slide uses a 'villain' framing by contrasting the high penalties of established peers against the absence of the target company (Valeant).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/21", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-21", "loopMatches": [], "arcBeatMatches": [ { "to": 21, "from": 17, "beatId": "f826f826-9857-48f7-81f2-57a1bd4e0426", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Preempt Rebuttal", "beatSlug": null, "evidence": "Addressing potential criticisms and rebuttals", "position": 3, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 22, "slideType": "villain_critique", "function": "name_villain", "notes": "Uses a direct quote from a U.S. Attorney to establish credibility and frame the villain.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/22", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-22", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 23, "slideType": "timeline", "function": "illustrate_case", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/23", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-23", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 24, "slideType": "expose_contradiction", "function": "expose_contradiction", "notes": "The slide uses a bulleted list to structure the case study details, focusing on legal and ethical misconduct.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/24", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-24", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 25, "slideType": "expose_contradiction", "function": "expose_contradiction", "notes": "The slide uses a quote to contrast the company's public admission of wrongdoing with their internal dismissal of business risk.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/25", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-25", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 26, "slideType": "key_messages", "function": "frame_situation", "notes": "This slide serves to preemptively address potential accusations of complicity or prior knowledge regarding Valeant's controversial specialty pharmacy practices.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/26", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-26", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 27, "slideType": "expose_contradiction", "function": "expose_contradiction", "notes": "The slide uses a structured list format to contrast Valeant's stated answers against the underlying unresolved questions.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/27", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-27", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 28, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a chronological list to frame expectations for the company's future.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/28", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-28", "loopMatches": [], "arcBeatMatches": [ { "to": 39, "from": 28, "beatId": "43f4c599-cad8-4b32-a83c-dc5fbf84126f", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Resolution", "beatSlug": "resolution", "evidence": "Conclusion and call to action", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 29, "slideType": "transition", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/29", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-29", "loopMatches": [], "arcBeatMatches": [ { "to": 39, "from": 28, "beatId": "43f4c599-cad8-4b32-a83c-dc5fbf84126f", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Resolution", "beatSlug": "resolution", "evidence": "Conclusion and call to action", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 30, "slideType": "kpi_overview", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/30", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-30", "loopMatches": [], "arcBeatMatches": [ { "to": 39, "from": 28, "beatId": "43f4c599-cad8-4b32-a83c-dc5fbf84126f", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Resolution", "beatSlug": "resolution", "evidence": "Conclusion and call to action", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 31, "slideType": "key_takeaways", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/31", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-31", "loopMatches": [], "arcBeatMatches": [ { "to": 39, "from": 28, "beatId": "43f4c599-cad8-4b32-a83c-dc5fbf84126f", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Resolution", "beatSlug": "resolution", "evidence": "Conclusion and call to action", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 32, "slideType": "valuation_table", "function": "show_valuation_bridge", "notes": "The slide uses a 'floor' valuation approach to argue for the stock's undervaluation.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/32", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-32", "loopMatches": [], "arcBeatMatches": [ { "to": 39, "from": 28, "beatId": "43f4c599-cad8-4b32-a83c-dc5fbf84126f", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Resolution", "beatSlug": "resolution", "evidence": "Conclusion and call to action", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 33, "slideType": "valuation_table", "function": "show_valuation_bridge", "notes": "The slide uses a DCF-style valuation bridge to demonstrate upside potential from the current share price of $111.50.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/33", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-33", "loopMatches": [], "arcBeatMatches": [ { "to": 39, "from": 28, "beatId": "43f4c599-cad8-4b32-a83c-dc5fbf84126f", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Resolution", "beatSlug": "resolution", "evidence": "Conclusion and call to action", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 34, "slideType": "valuation_table", "function": "quantify_opportunity", "notes": "The slide uses a DCF-style valuation bridge to calculate potential returns based on 2020 EPS projections.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/34", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-34", "loopMatches": [], "arcBeatMatches": [ { "to": 39, "from": 28, "beatId": "43f4c599-cad8-4b32-a83c-dc5fbf84126f", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Resolution", "beatSlug": "resolution", "evidence": "Conclusion and call to action", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 35, "slideType": "transition", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/35", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-35", "loopMatches": [], "arcBeatMatches": [ { "to": 39, "from": 28, "beatId": "43f4c599-cad8-4b32-a83c-dc5fbf84126f", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Resolution", "beatSlug": "resolution", "evidence": "Conclusion and call to action", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 36, "slideType": "cite_precedent", "function": "cite_precedent", "notes": "This slide serves as a historical precedent for corporate fraud and due diligence failure.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/36", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-36", "loopMatches": [], "arcBeatMatches": [ { "to": 39, "from": 28, "beatId": "43f4c599-cad8-4b32-a83c-dc5fbf84126f", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Resolution", "beatSlug": "resolution", "evidence": "Conclusion and call to action", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 37, "slideType": "cite_precedent", "function": "cite_precedent", "notes": "Uses historical precedent to frame current investment thesis.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/37", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-37", "loopMatches": [], "arcBeatMatches": [ { "to": 39, "from": 28, "beatId": "43f4c599-cad8-4b32-a83c-dc5fbf84126f", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Resolution", "beatSlug": "resolution", "evidence": "Conclusion and call to action", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 38, "slideType": "ceo_quote", "function": "establish_context", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/38", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-38", "loopMatches": [], "arcBeatMatches": [ { "to": 39, "from": 28, "beatId": "43f4c599-cad8-4b32-a83c-dc5fbf84126f", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Resolution", "beatSlug": "resolution", "evidence": "Conclusion and call to action", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a077f08347fa", "docSlug": "4934d687cb38", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-10-30 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 39, "slideType": "closing_ask", "function": "closing_ask", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/39", "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-39", "loopMatches": [], "arcBeatMatches": [ { "to": 39, "from": 28, "beatId": "43f4c599-cad8-4b32-a83c-dc5fbf84126f", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Resolution", "beatSlug": "resolution", "evidence": "Conclusion and call to action", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-a530d644219b", "docSlug": "2c06f582b147", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square Holdings", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2016-03-21 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 1, "slideType": "other", "function": "summarize", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/WKCYETnuiryVphSJAlUsJ1S8P9mh_FyMsCktxncmrbg/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yYzA2ZjU4MmIxNDcvcDAwMS5qcGc", "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a530d644219b/1", "deckHref": "/decks/019dd923-622c-750b-8b9b-a530d644219b", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a530d644219b#slide-1", "loopMatches": [], "arcBeatMatches": [ { "to": 1, "from": 1, "beatId": "dbbad077-33ab-463d-bc8c-407beb569982", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Attention", "beatSlug": "aida-attention", "evidence": "Initial communication", "position": 0, "confidence": 0.6, "parentBeatName": "Hook", "parentBeatSlug": "hook" } ], "imagePathAlt": "https://imgproxy.kitesheet.com/Oyvti9HrbGxoHIDQmTpy5KOXNk7aZbVQwcJzKG-OJ6w/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yYzA2ZjU4MmIxNDcvcDAwMS5wbmc", "thumbSrc": "https://imgproxy.kitesheet.com/SrNzrV_DxX1RetZwCUM2WjGoji6X1jBYpVdV_uwC4i8/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yYzA2ZjU4MmIxNDcvcDAwMS5qcGc", "thumbSrcAlt": "https://imgproxy.kitesheet.com/sVNK-pNfB4oLnIXB6KA3gNqkN6euj7XkLj81I2e-Cdg/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yYzA2ZjU4MmIxNDcvcDAwMS5wbmc" }, { "docId": "019dd923-622c-750b-8b9b-a88f4b1599da", "docSlug": "2a2da42210b1", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square Holdings", "documentKindSlug": "press-release", "documentKindLabel": "Press release", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2016-03-21 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 1, "slideType": "press-release", "function": "summarize", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/XkETKPN-TvUU2wF3XyhBd_8iyfC0J8TWixN9HYX367U/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yYTJkYTQyMjEwYjEvcDAwMS5qcGc", "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-a88f4b1599da/1", "deckHref": "/decks/019dd923-622c-750b-8b9b-a88f4b1599da", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a88f4b1599da#slide-1", "loopMatches": [], "arcBeatMatches": [ { "to": 1, "from": 1, "beatId": "376645f4-9b64-4592-a1d1-5b0a48ed4eea", "arcName": "AIDA", "arcSlug": "aida", "beatName": "Attention", "beatSlug": "aida-attention", "evidence": "The press release aims to grab the attention of shareholders regarding developments at Valeant Pharmaceuticals International, Inc.", "position": 0, "confidence": 0.8, "parentBeatName": "Hook", "parentBeatSlug": "hook" } ], "imagePathAlt": "https://imgproxy.kitesheet.com/hY2ot2XmnVingQA293aFySRoBXiY-1UAghBvU2ImeoM/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yYTJkYTQyMjEwYjEvcDAwMS5wbmc", "thumbSrc": "https://imgproxy.kitesheet.com/S2qiVGxxkPthQD6Du653fgO4M4NbiI4qTDV8CObmMqE/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yYTJkYTQyMjEwYjEvcDAwMS5qcGc", "thumbSrcAlt": "https://imgproxy.kitesheet.com/yr1IzIAQBtVdpHLHLcjVqqItIHDpKHiULIhJ6PBEF1E/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yYTJkYTQyMjEwYjEvcDAwMS5wbmc" } ] }